ArrowMark Partners
VC Fund
Denver, United States
ArrowMark Partners is an SEC-registered investment adviser based in Denver, Colorado. Their investment objective is clear: deliver consistent, asymmetric, non-correlated, risk-adjusted returns by applying fundamental research across the capital structure. They focus on compounding wealth by delivering unique, client-driven and absolute returnsolutions.
- Total investments:
- 74
- Last investment:
- Lead investor:
- 14%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ArrowMark Partners invests in
BiotechnologyHealth CarePharmaceuticalMedicalTherapeutics
Stages ArrowMark Partners invests in
Series CSeries BSeries ESeries DPost-IPO Equity
Countries ArrowMark Partners invests in
United StatesChinaFranceBermudaUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Novoseller
|
|||
Tony Yao
|
|||
David Corkins
|
|||
Karen Reidy
|
|||
Vipul Shah
|
Investment Focus
Industry
- Biotechnology 41 (55%)
- Health Care 22 (30%)
- Pharmaceutical 14 (19%)
- Medical 13 (18%)
- Therapeutics 13 (18%)
Stage
- Series C 20 (27%)
- Series B 19 (26%)
- Series E 6 (8%)
- Series D 5 (7%)
- Post-IPO Equity 4 (5%)
Country
- United States 52 (70%)
- China 1 (1%)
- France 1 (1%)
- Bermuda 1 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michael Novoseller
Managing Director and Investment Committee Member
|
Managing Director and Investment Committee Member | Total investments: 0 | Find email | |
|
Tony Yao
Portfolio Manager
|
Portfolio Manager | Total investments: 3 | Find email | |
|
David Corkins
Co-Founding Partner & Portfolio Manager
|
Co-Founding Partner & Portfolio Manager | Total investments: 0 | Find email | |
|
Karen Reidy
Co-Founding Partner & Portfolio Manager
|
Co-Founding Partner & Portfolio Manager | Total investments: 0 | Find email | |
|
Vipul Shah
Managing Director and Investment Committee Member
|
Managing Director and Investment Committee Member | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Skyryse
|
Skyryse is an aerospace technology company that develops pilot assistance and autonomous flight systems designed to support safer, more accessible helicopter operations. The company’s technology integrates flight control software, sensors, and interface systems that help pilots execute complex maneuvers with enhanced precision and situationalawareness, particularly in challenging environments such as urban, offshore, or emergency response missions. Skyryse provides solutions that automate key phases of flight, including takeoff, navigation, and landing, by translating high-level inputs into coordinated control actions that align with aircraft performance and safety parameters. The company also works with OEMs, operators, and regulatory partners to certify and deploy its systems within existing rotorcraft platforms, enabling integration with avionics, mission planning, and training workflows. Its platform supports real-time data processing, redundancy management, and human-machine interaction design to assist crews while maintaining compliance with aviation safety standards. Skyryse engages with technical teams and stakeholders across civil, commercial, and public safety aviation sectors to advance adoption of automated flight capabilities that enhance operational consistency and pilot effectiveness. | $300M / Series C / Feb 03, 2026 | |
Frontier Medicines
|
Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $20M / Series C / Jun 25, 2024 | |
SmartLabs
|
SmartLabs designs, builds, and operates integrated, enterprise-grade research environments, including multifunctional research and development labs, vivariums, process development, pilot-scale manufacturing, and cGMP suites for companies of all sizes. | $48M / Series C / Jan 18, 2024 | |
Arvinas
|
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. | $350M / Post-IPO Equity / Nov 27, 2023 | |
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $100M / Series D / Aug 30, 2023 | |
Checkerspot
|
Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers andenables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials. | $55M / Series C / Feb 14, 2023 | |
Sonendo
|
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $63M / Post-IPO Equity / Sep 23, 2022 | |
Aktis Oncology
|
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy.Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. | $84M / Series A / Aug 25, 2022 | |
Dren Bio
|
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets. | $65M / Series B / Jun 14, 2022 | |
|
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $57M / Series C / Feb 17, 2022 | |
| See all 74 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does ArrowMark Partners invest in?
ArrowMark Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Series B stage. Most of the 74 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ArrowMark Partners?
Public channels for ArrowMark Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ArrowMark Partners?
The team at ArrowMark Partners includes Michael Novoseller (Managing Director and Investment Committee Member), Tony Yao (Portfolio Manager) and David Corkins (Co-Founding Partner & Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
